Effect of platelet activating factor on the kinetics of LDL oxidation in vitro.
Oxidatively modified low-density-lipoprotein (LDL) might contribute to the atherosclerotic process. This study was performed to examine an effect of platelet-activating factor (PAF) and of synthetic PAF analogs on Cu(II) induced oxidation of LDL in vitro: The D- and L-isomers of PAF and analogs with short-chain sn-2-substituents, 1-O-alkyl-2-butyryl-sn-glycero-3-phosphocholine and 1-O-alkyl-2-heptanoyl-sn-glycero-3-phosphocholine, were found to be the most effective inhibitors of LDL oxidation. Oxidation was inhibited completely at PAF concentrations above 100 microM. Lyso-PAF and analogs carrying longer chains at the sn-2 position were less effective. These results thus provide evidence for the involvement of other parameters in LDL oxidation beyond the content of natural antioxidants like vitamin E and beta-carotene.
Deigner
H P
HP
Pharmazeutisch-Chemisches Institut, Universität Heidelberg, Germany.
Dresel
H A
HA
D003300:Copper / Q000502:physiology; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D019787:Linoleic Acid; D008041:Linoleic Acids / Q000378:metabolism; D008075:Lipoproteins, HDL / Q000502:physiology; D008077:Lipoproteins, LDL / Q000097:blood / Q000378:metabolism*; D010084:Oxidation-Reduction; D010972:Platelet Activating Factor / Q000031:analogs & derivatives / Q000494:pharmacology / Q000502:physiology*; D013329:Structure-Activity Relationship
D008041:Linoleic Acids; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D010972:Platelet Activating Factor; D003300:Copper; D019787:Linoleic Acid